Thomas Bachmann is new Chief Executive Officer of the Eppendorf Group

Thomas Bachmann became Chief Executive Officer of the Eppendorf Group on August 1, 2015. Following the departure of Eppendorf's previous CEO, the company's Chief Financial Officer, Detmar Ammermann, had exercised the function of Spokesman of the Management Board on an interim basis in addition to his responsibilities as CFO. Bachmann, who has been a member of the Eppendorf Supervisory Board since 2013, came to Eppendorf from his position as President of the Bruker BioSpin Group. He has been active in the life science sector since 2005, when he took on the overall management of the globally active Tecan Group, which is headquartered in Switzerland. "We are very pleased that we have been able to win Thomas Bachmann as our Chief Executive Officer," said Klaus Fink, Chairman of the Supervisory Board of the Eppendorf Group. "He has demonstrated his expertise and his strategic foresight in many ways during more than 25 years of experience in international management positions." Bachmann explains: "Eppendorf is an innovative, customer-oriented company with a strong, well-known brand and a global orientation, and it succeeds again and again in making important contributions to analytic, medical, diagnostic and life science laboratories. I am looking forward to working with Eppendorf's very competent and committed global management to develop the company sustainably and successfully in the years to come."

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …